- Trials with a EudraCT protocol (5,082)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5,082 result(s) found for: Cancer chemotherapy.
Displaying page 1 of 255.
| EudraCT Number: 2013-002564-69 | Sponsor Protocol Number: 410/56 | Start Date*: 2014-04-11 | |||||||||||
| Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH | |||||||||||||
| Full Title: Double-blind, placebo-controlled multicenter phase II trial to evaluate the efficacy and safety of romiplostim for the treatment of chemotherapy-induced thrombocytopenia in subjects with relapse... | |||||||||||||
| Medical condition: Patients with relapsed ovarian cancer (2nd and 3rd line) treated with chemotherapy according to AGO guidelines who develop thrombocytopenia grade 3 and/or grade 4. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003660-13 | Sponsor Protocol Number: E-DIS-2-1705 | Start Date*: 2018-02-21 |
| Sponsor Name:Centre Oscar Lambret | ||
| Full Title: Phase II Randomized Study Measuring the Interest of Pursuing or Not the chemotherapy for Non-progressive Patients With Metastatic Esophageal Squamous-cell Cancer After 6 Weeks of LV5FU2-paclitaxel ... | ||
| Medical condition: Patients suffering from squamous-cell type esophageal cancer histologically proved and with metastatic disease measurable according to RECIST criteria. Patients with metachronous metastasis and w... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-001211-75 | Sponsor Protocol Number: D0816C00002 | Start Date*: 2013-11-15 | ||||||||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | ||||||||||||||||||||||||||||
| Full Title: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Comple... | ||||||||||||||||||||||||||||
| Medical condition: BRCA Mutated Platinum Sensitive Relapse (PSR) high grade Serous Ovarian Cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed) ES (Ongoing) FR (Ongoing) PL (Completed) DE (Completed) BE (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2015-000658-39 | Sponsor Protocol Number: AkupresSNP | Start Date*: 2016-07-11 |
| Sponsor Name:Region Jönköpings län | ||
| Full Title: Randomized multicenter study of Acupressure combined with personalized antiemetics based on genetic variations (SNPs) in women undergoing neoadjuvant or adjuvant chemotherapy EC / FEC against breas... | ||
| Medical condition: Nausea in conjuction with neoadjuvant or adjuvant chemotherapy (FEC/EC) for patients with breast cancer. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-001006-28 | Sponsor Protocol Number: 20170770 | Start Date*: 2019-09-13 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Amgen Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of No... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GR (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) AT (Completed) HU (Completed) ES (Ongoing) RO (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-000556-35 | Sponsor Protocol Number: D910LC00001 | Start Date*: 2020-12-01 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected ... | |||||||||||||
| Medical condition: Completely Resected Stage II-III NSCLC | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) NL (Prematurely Ended) DK (Prematurely Ended) BG (Completed) HU (Prematurely Ended) DE (Completed) BE (Completed) SE (Prematurely Ended) PL (Completed) CZ (Completed) GR (Completed) IT (Prematurely Ended) FR (Completed) RO (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-001452-36 | Sponsor Protocol Number: XM02-02-INT | Start Date*: 2004-06-30 |
| Sponsor Name:BioGeneriX | ||
| Full Title: Efficacy and Safety of XM 02 compared to Filgrastim in patients with breast cancer receiving chemotherapy. Multinational, multicentre, randomised, controlled study | ||
| Medical condition: Patients with breast cancer high risk stage II or stage III/IV (classification according to American Joint Committee on Cancer [AJCC] receiving chemotherapy and developing Neutropenia due to chemot... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Completed) LT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-005850-27 | Sponsor Protocol Number: NAPEER | Start Date*: 2022-05-31 |
| Sponsor Name:Oslo University Hospital | ||
| Full Title: An open label phase II trial in hormone receptor positive breast cancer patients randomized to neoadjuvant chamotherapy with or without bevacizumab (if ViRP signature positive) followed by endocrin... | ||
| Medical condition: Hormone receptor positive primary breast cancer with tumor measuring > 2.0 cm that will be recommended chemotherapy and antihormone therapy according to the treatment guidelines for curative breast... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-001094-16 | Sponsor Protocol Number: PROACT | Start Date*: 2017-08-08 | |||||||||||
| Sponsor Name:South Tees NHS Foundation Trust | |||||||||||||
| Full Title: Preventing cardiac damage in patients treated for breast cancer and lymphoma: a phase 3 Randomised, Open label, blinded endpoint, trial of enalapril to prevent Anthracycline-induced CardioToxicity ... | |||||||||||||
| Medical condition: Prevention of cardiotoxicity | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-004429-41 | Sponsor Protocol Number: BAY43-9006/12007 | Start Date*: 2008-10-03 | |||||||||||||||||||||
| Sponsor Name:Bayer Healthcare AG | |||||||||||||||||||||||
| Full Title: A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a ... | |||||||||||||||||||||||
| Medical condition: The study population will include patients with FIGO stage III or IV ovarian cancer or primary peritoneal cancer who have had extensive debulkment surgery and who have achieved a clinical complete ... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: BE (Completed) NL (Completed) IT (Completed) ES (Completed) FR (Completed) FI (Completed) DE (Completed) PL (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2012-005337-37 | Sponsor Protocol Number: ONC-2012-002 | Start Date*: 2013-05-07 | |||||||||||
| Sponsor Name:Istituto Clinico Humanitas | |||||||||||||
| Full Title: ANTI-MULLERIAN HORMONE (AMH) AS A MARKER OF OVARIAN RESERVE IN YOUNG BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY + GnRH ANALOGUE | |||||||||||||
| Medical condition: Female subjects, aged <40yrs receiving adjuvant chemotherapy and ovarian suppression by means of GnRHa with the aim to assess the role of AMH as surrogate marker of the preservation of ovarian rese... | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-002417-36 | Sponsor Protocol Number: CAPTEM | Start Date*: 2014-08-28 | ||||||||||||||||
| Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori | ||||||||||||||||||
| Full Title: An open-label, randomized, multicenter, phase II trial designed to estimate the activity of CAPTEM combination versus FOLFIRI as second line treatment in patients who have progressed on or after fi... | ||||||||||||||||||
| Medical condition: colorectal cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2006-002860-25 | Sponsor Protocol Number: ML19944 | Start Date*: 2006-09-27 | |||||||||||
| Sponsor Name:Roche Hungary Ltd. | |||||||||||||
| Full Title: A multicenter randomized phase II trial to compare trastuzumab (Herceptin®) continuation or discontinuation in combination with 2nd-line chemotherapies after progression on a 1st-line chemotherapy ... | |||||||||||||
| Medical condition: Metastacic breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: HU (Completed) EE (Completed) LT (Completed) SK (Completed) LV (Prematurely Ended) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-002727-11 | Sponsor Protocol Number: CRO-2020-043 | Start Date*: 2023-08-02 | |||||||||||||||||||||
| Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO | |||||||||||||||||||||||
| Full Title: Neoadjuvant Chemotherapy followed by Pre-operative Chemoradiation and Consolidation Chemotherapy before Surgery in High Risk Rectal Cancer: Multicentric Phase II Study. | |||||||||||||||||||||||
| Medical condition: Patients with locally advanced, potentially resectable, Middle-Distal Rectal Carcinoma, stage T3c-d N1-2, MRF + or T4N0-2, EMVI - / + (High-Risk) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2015-001097-18 | Sponsor Protocol Number: CA209-331 | Start Date*: 2015-09-15 | |||||||||||||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
| Full Title: An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinumbased First Line Chemotherapy | |||||||||||||||||||||||
| Medical condition: Relapsed Small Cell Lung Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: CZ (Completed) AT (Completed) DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) HU (Completed) GR (Completed) PL (Completed) ES (Completed) FR (Completed) RO (Ongoing) IT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2011-003399-36 | Sponsor Protocol Number: MK-4214-008 | Start Date*: 2011-10-28 | |||||||||||||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||||||||||||
| Full Title: A Phase III Randomized, Double-Blind, Active-Controlled Clinical Trial to Study the Efficacy and Safety of MK-4214 (filgrastim) and Neupogen™ as an Adjunct to Combination Chemotherapy with Doxorubi... | |||||||||||||||||||||||
| Medical condition: Breast Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: LV (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2015-000380-13 | Sponsor Protocol Number: CP-MGAH22-04 | Start Date*: 2015-09-02 | |||||||||||||||||||||
| Sponsor Name:MacroGenics, Inc. | |||||||||||||||||||||||
| Full Title: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 The... | |||||||||||||||||||||||
| Medical condition: Metastatic or Locally Advanced HER2-positive Breast Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BE (Completed) DE (Completed) PT (Completed) CZ (Completed) AT (Completed) FI (Completed) ES (Completed) DK (Completed) FR (Ongoing) PL (Completed) IT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2017-001195-35 | Sponsor Protocol Number: CA209-9LA | Start Date*: 2017-09-20 | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
| Medical condition: Stage IV Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) IE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Completed) RO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-004585-15 | Sponsor Protocol Number: Cat-Ovar_2011 | Start Date*: 2012-11-29 | |||||||||||
| Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
| Full Title: Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal ca... | |||||||||||||
| Medical condition: This is an international, explorative, open-label, prospective, non-randomized multicenter phase II study to assess the feasibility and clinical activity of initial intraperitoneal catumaxomab foll... | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-001322-26 | Sponsor Protocol Number: SOV01 | Start Date*: 2013-12-02 | |||||||||||
| Sponsor Name:SOTIO a.s. | |||||||||||||
| Full Title: A randomized, open-label, three-arm, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with ... | |||||||||||||
| Medical condition: epithelial ovarian carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: DE (Completed) CZ (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
